Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R.sup.1, R.sup.2, L.sup.1, and L.sup.2 are as defined herein. ##STR00001##

The invention relates to a device for treating an individual suffering from cardiac or circulatory arrest or from a stroke, comprising a blood withdrawal device (BE) that is applied to the individual (P), an analysis unit (BA) which is directly or indirectly connected to the blood withdrawal device for detecting a blood analysis result (BAE) providing at least one characteristic of the blood, directly or indirectly connected to a blood return device (BR) that is applied to the individual (P) and is designed to deliver a substance to the individual via the return device (BR).

The present invention is a method of producing a lanthanum carbonate hydroxide or lanthanum oxycarbonate which has improved properties. The method involves the use of a water soluble lanthanum and a water soluble non-alkali metal carbonate or bicarbonate. The resulting material can be used as a phosphate binder individually or for treating patients with hyperphosphatemia.

Described herein is a process suitable for extracorporeal lung support that relies on exposing blood, separated by a semipermeable membrane from the dialysis liquid. The dialysis liquid comprises a buffering agent and has a high buffering capacity for H+ ions. Carbon dioxide, bicarbonate and hydrogen cations can be efficiently transported across a semipermeable membrane to the dialysis liquid. This also allows for the regeneration and recycling of the dialysis liquid, and thus for its repeated use. The versatility of the dialysis liquid allows adjusting the pill of the dialysis liquid, add fluids to the dialysis liquid and/or to the blood in the extracorporeal circuit and to remove substances from the blood in the extracorporeal circuit, depending on the conditions and needs. Thus, the process is versatile, and suitable for treating or preventing respiratory acidosis, metabolic acidosis, diseases associated with lung malfunction and/or kidney malfunction and/or liver malfunction.

Compounds according to Formula I are potent inhibitors of Arginase I and II activity: ##STR00001##
where R.sup.1, R.sup.2, R.sup.3, R.sup.4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I):

##STR00001##

wherein R.sup.1, R.sup.2, L.sup.1, and L.sup.2 are as defined herein.

The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to conventional iron sucrose compositions.

A perfusion method includes a) cleaning a blood vessel of an organ by causing a first perfusate to flow into the blood vessel and letting the first perfusate out of the organ through the blood vessel, and b) after the operation a), preserving the organ while causing a second perfusate to flow into the blood vessel and letting the second perfusate out of the organ through the blood vessel. The first perfusate and the second perfusate each contain a biocompatible solution and a serine protease and have an osmotic pressure ratio higher than or equal to 1 and lower than or equal to 5 relative to the saline solution. The concentration of the serine protease in the second perfusate is lower than that in the first perfusate. Accordingly, it is possible to dissolve thrombi in the blood vessel or prevent the formation of new thrombi during organ perfusion treatment.

The present invention involves novel urea compositions for oral administration, that are useful for treatment or management of hyponatremia. Also disclosed are novel methods of making the urea compositions.